News
Astellas’ Xtandi bags additional MHRA approval in prostate cancer
Japanese pharma company Astellas has announced that its prostate cancer therapy Xtandi has gained an approval for an additional indication from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).